Evaluation of salivary levels of beta amyloid in patients with Alzheimer’s disease

Abstract

AbstractBackgroundSalivary analysis of amyloid beta protein levels in Alzheimer’s disease patients and research participants without Alzheimer’s disease.MethodThis is a case‐control study carried out in patients with a diagnosis of probable AD and cognitively healthy patients without AD. There were 3 groups, totaling 76 people: group 1 with AD; Group 2 without AD (under 59 years old) and group 3 without AD (over 60 years old). Ethics committee opinion n° 3,130,636. Salivary analysis of Ab‐40 and Ab‐42 performed by the ELISA method.ResultOur investigations for salivary AB42 showed slightly higher levels in male and female AD patients compared to healthy ones. The general AB42 group for AD was superior to the general group of healthy ones, demonstrating the feasibility of using saliva as a diagnostic element for AD.ConclusionAmyloid beta protein in fractions 40 and 42 amino acids (Ab1‐40 and Ab1‐42) were expressed in higher concentrations in AD patients and reduced in healthy ones, strengthening the hypothesis of the use of this fluid as an adjuvant in the diagnosis of Alzheimer’s Disease.